129 related articles for article (PubMed ID: 25271366)
21. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor-independent inhibition of tumor necrosis factor-alpha gene expression by phytoestrogen equol is mediated by blocking nuclear factor-kappaB activation in mouse macrophages.
Kang JS; Yoon YD; Han MH; Han SB; Lee K; Kang MR; Moon EY; Jeon YJ; Park SK; Kim HM
Biochem Pharmacol; 2005 Dec; 71(1-2):136-43. PubMed ID: 16288994
[TBL] [Abstract][Full Text] [Related]
23. Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload.
Kiguchi T; Ito Y; Kimura Y; Ohyashiki K
Int J Hematol; 2009 May; 89(4):546-548. PubMed ID: 19363706
[No Abstract] [Full Text] [Related]
24. Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.
Pullarkat V; Sehgal A; Li L; Meng Z; Lin A; Forman S; Bhatia R
Leuk Res; 2012 Aug; 36(8):966-73. PubMed ID: 22502920
[TBL] [Abstract][Full Text] [Related]
25. Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats.
Brewer C; Otto-Duessel M; Lykkesfeldt J; Nick H; Wood JC
Exp Hematol; 2012 Oct; 40(10):820-7. PubMed ID: 22713799
[TBL] [Abstract][Full Text] [Related]
26. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
27. [Hematologic improvement with deferasirox following tandem antithymocyte globulin treatment in a transfusion-dependent patient with severe aplastic anemia].
Jomen W; Kuroda H; Yamada M; Matsuno T; Sato M; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Nagashima K; Iyama S; Miyanishi K; Kobune M; Kato J
Rinsho Ketsueki; 2013 Nov; 54(11):2047-52. PubMed ID: 24305537
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic control of NF-κB-dependent FAS gene transcription during progression of myelodysplastic syndromes.
Ettou S; Humbrecht C; Benet B; Billot K; d'Allard D; Mariot V; Goodhardt M; Kosmider O; Mayeux P; Solary E; Fontenay M
Mol Cancer Res; 2013 Jul; 11(7):724-35. PubMed ID: 23604035
[TBL] [Abstract][Full Text] [Related]
29. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
30. Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
Quarta A; Melpignano A; Quarta G
Acta Haematol; 2011; 125(4):219-21. PubMed ID: 21266801
[TBL] [Abstract][Full Text] [Related]
31. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
32. Propanil inhibits tumor necrosis factor-alpha production by reducing nuclear levels of the transcription factor nuclear factor-kappab in the macrophage cell line ic-21.
Frost LL; Neeley YX; Schafer R; Gibson LF; Barnett JB
Toxicol Appl Pharmacol; 2001 May; 172(3):186-93. PubMed ID: 11312646
[TBL] [Abstract][Full Text] [Related]
33. Exjade (ICL 670): A new oral iron chelator.
Agarwal MB
J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
[TBL] [Abstract][Full Text] [Related]
34. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
Wimazal F; Nösslinger T; Baumgartner C; Sperr WR; Pfeilstöcker M; Valent P
Eur J Clin Invest; 2009 May; 39(5):406-11. PubMed ID: 19320908
[TBL] [Abstract][Full Text] [Related]
35. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
36. Iron chelation decreases human immunodeficiency virus-1 Tat potentiated tumor necrosis factor-induced NF-kappa B activation in Jurkat cells.
Shatrov VA; Boelaert JR; Chouaib S; Dröge W; Lehmann V
Eur Cytokine Netw; 1997 Mar; 8(1):37-43. PubMed ID: 9110146
[TBL] [Abstract][Full Text] [Related]
37. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes.
Hartmann J; Braulke F; Sinzig U; Wulf G; Maas JH; Konietschke F; Haase D
Leuk Res; 2013 Mar; 37(3):327-32. PubMed ID: 23259989
[TBL] [Abstract][Full Text] [Related]
38. Deferasirox: the new oral iron chelator.
Dubey AP; Sudha S; Parakh A
Indian Pediatr; 2007 Aug; 44(8):603-7. PubMed ID: 17827637
[TBL] [Abstract][Full Text] [Related]
39. Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia.
Lee JW; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Pediatr Hematol Oncol; 2011 Nov; 28(8):718-20. PubMed ID: 22023466
[No Abstract] [Full Text] [Related]
40. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.
Koh KN; Park M; Kim BE; Im HJ; Seo JJ
J Pediatr Hematol Oncol; 2010 Nov; 32(8):611-4. PubMed ID: 20881872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
